Skip to main content

Table 1 Experimental design, animal number and analyses performed per time-point (tp) within each experimental group.

From: Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

 

Subacute MPTP

Subchronic MPTP

Days after MPTP discontinuation

Analyses

mice/tp

-7

0

+1

+3

+7

0

+1

+3

+7

+21

+30

+40

Rotarod

10

+

+

+

+

+

       

Neurochem.

5

 

+

  

+

 

+

 

+

+

+

+

Immunohistochem.

5

     

+

+

+

+

+

+

+

Microglia markers

5

     

+

+

+

+

   

Gene expression

4

     

+

+

 

+

+

+

+

Western blot

4

     

+

+

+

+

+

 

+

  1. Young (3-5 month-old) and ageing (9-11 month-old) C57Bl/6 mice fed with a control, flurbiprofen or HCT1026 diets (30 mg kg-1) starting at -10 d, underwent an MPTP treatment according to the subacute (n = 4 intraperitoneal, i.p., injections of MPTP-HCl, 15 mg kg-1 free base, 2 hours apart in one day) or subchronic (n = 5 intraperitoneal, i.p., injections of MPTP-HCl, at 5, 15 or 30 mg kg-1 free base, every 24 h), injection paradigms. Age-matched mice fed with the different diets received physiologic saline (NaCl, 10 ml kg-1) and served as controls. Mice number and timepoints (tp) for each experimental protocol for each set of analyses/tp, are indicated. Striatum and ventral midbrains tissues were processed for RT-PCR or western blotting, as reported according to the different determinations. For immunohistochemical analyses, on the day of sacrifice mice were anesthetized and transcardially perfused, the brains processed as indicated. See Methods section for details.